Abstract
We recently described an unconventional mode of gene regulation in budding yeast by which transcriptional and translational interference collaborate to down-regulate protein expression. Developmentally timed transcriptional interference inhibited production of a well translated mRNA isoform and resulted in the production of an mRNA isoform containing inhibitory upstream open reading frames (uORFs) that prevented translation of the main ORF. Transcriptional interference and uORF-based translational repression are established mechanisms outside of yeast, but whether this type of integrated regulation was conserved was unknown. Here we find that, indeed, a similar type of regulation occurs at the locus for the human oncogene MDM2. We observe evidence of transcriptional interference between the two MDM2 promoters, which produce a poorly translated distal promoter-derived uORF-containing mRNA isoform and a well-translated proximal promoter-derived transcript. Down-regulation of distal promoter activity markedly up-regulates proximal promoter-driven expression and results in local reduction of histone H3K36 trimethylation. Moreover, we observe that this transcript toggling between the two MDM2 isoforms naturally occurs during human embryonic stem cell differentiation programs.
Keywords: gene expression regulation, MDM2, LUTI, transcript isoform, uORF translation
Gene expression regulation enables differential decoding of identical genetic material. It has generally been studied as a set of sequential processes, with transcription setting the core pattern of expression and translational and post-translational regulation modulating the final output. The concept of an exclusively linear model for the regulation of genetic information decoding is partly the result of the largely isolated discovery and subsequent study of each regulatory step. This approach has been necessary for and successful in providing a deep understanding of the biochemical mechanisms that mediate gene regulation, as well as for defining the types of regulatory mechanisms that exist at each level. Such regulatory mechanisms include, for example, transcriptional interference, in which transcription from one promoter locally represses transcription from another (Hausler and Somerville 1979; Adhya and Gottesman 1982; Cullen et al. 1984; Emerman and Temin 1984; Proudfoot 1986; Hirschman et al. 1988; Corbin and Maniatis 1989; Boussadia et al. 1997; Greger et al. 2000; Martens et al. 2004; Kim et al. 2012; Van Werven et al. 2012; Kim et al. 2016). Transcriptional repression by this mechanism has been associated with cis-enrichment of inhibitory chromatin marks, typically by production of a noncoding transcript (Carrozza et al. 2005; Kim et al. 2012; Van Werven et al. 2012; Kim et al. 2016). An example of a similarly established translational repression mechanism is based on translation of upstream ORFs (uORFs) in the 5′ leader region of some mRNAs at the expense of ORF translation [reviewed in (Wethmar et al. 2010; Barbosa et al. 2013; Wethmar 2014; Hinnebusch et al. 2016)]. Typically, uORF-mediated translational repression is viewed as a switch-like mechanism, where the uORFs prevent translation of the downstream ORF under certain conditions, but this repression can be bypassed under other conditions.
Recently, we described a form of gene regulation that relies on the obligate coupling of transcriptional interference and uORF-mediated translational repression to downregulate protein expression (Figure 1A; Chen et al. 2017; Chia et al. 2017). During budding yeast meiosis, the amount of protein for the conserved kinetochore protein Ndc80 is determined by toggling between two functionally distinct NDC80 mRNA isoforms. The mRNA isoform produced from a distal promoter cannot be efficiently translated due to uORF translation that prevents ribosomes from reaching and translating the NDC80 ORF, and the transcription of this isoform interferes with the proximal NDC80 promoter activity in cis. In this manner, production of a 5′-extended mRNA isoform inhibits Ndc80 protein production (Chen et al. 2017; Chia et al. 2017). In the case of NDC80, the uORF-mediated repression appears to be constitutive, conditional only on the existence of the 5′-extended transcript, rather than condition-specific like the best studied regulatory uORF cases [(Mueller and Hinnebusch 1986; Vattem and Wek 2004), for example]. Thus, translational down-regulation by uORFs is simply a consequence of the choice of an upstream transcription start site. Re-expression of Ndc80 protein is achieved by a developmentally induced switch in promoter usage, from distal to proximal, during meiotic progression.
Figure 1.
Illustrations of LUTI-based gene repression and MDM2 gene locus, A. Model for LUTI-based gene repression. Top panel: LUTI mRNA production causes an increase in the co-transcriptional H3K36me3 marks at the proximal gene promoter and transcriptional repression of the canonical mRNA isoform. Because LUTI mRNA is not well translated due to uORFs in its extended 5′ leader and because the well-translated canonical mRNA is repressed, the net effect of LUTI mRNA production is the downregulation of translation from the LUTI target gene locus. Bottom panel: In the absence of LUTI expression, transcription from the canonical gene promoter occurs, leading to translation. B. Illustration of the MDM2 gene structure. MDM2 is transcribed from two different transcription start sites (TSS1 and TSS2) regulated by two different promoters (P1 and P2). Transcription from the distal TSS1 produces a 5′-extended, uORF-containing transcript, which is poorly translated. Hereafter, the P1 promoter-driven transcript isoform is referred to as MDM2LUTI, while the P2-driven isoform, transcribed from the proximal TSS2 is referred to as MDM2PROX. p53 RE refers to the location of the p53 response element within the P2 promoter.
Improved methodology for genome-wide gene expression measurements have resulted in a more complete characterization of the set of transcripts expressed and regions translated than was previously possible. These studies have provided evidence for translation of thousands of uORFs and widespread existence of alternate transcript isoforms [(Ingolia et al. 2009; Ingolia et al. 2011; Brar et al. 2012; Sterne-Weiler et al. 2013; Dieudonné et al. 2015; Floor and Doudna 2016; Wang et al. 2016), for example], including during the yeast meiotic program. Despite their prevalence, the biological impact of both alternative transcript production and uORF translation to gene expression output in most of these newly identified cases has been unclear. Using analyses of parallel global mRNA, translation, and protein datasets, we found that many of the uORFs and alternate transcripts seen during the yeast meiotic program were indicative of the mode of coordinate regulation seen for NDC80, with at least 379 other genes showing protein levels that are driven by this type of integrated transcriptional and translational control over time through meiotic development (Cheng et al. 2018). It was also recently found that this mode of regulation functions to mediate down-regulation of proteins involved in aerobic respiration as a core part of the unfolded protein response [UPR; (Van Dalfsen et al., 2018)].
We noted that some of the hallmarks of the integrated mode of gene repression that were seen for NDC80 regulation, and thus used to annotate new cases in yeast, are also known to be common in mammals. For example, almost half of human genes show evidence of alternative promoter usage, resulting in transcript isoforms that differ in their 5′ leader (Wang et al. 2016). Additionally, transcripts with extended 5′ leaders that contain uORFs result, in some cases, in a poorly translated transcript compared to isoforms with shorter 5′ leaders (Law et al. 2005; Floor and Doudna 2016). Alternative uORF-containing transcripts were also previously defined for several individual mammalian genes, including Mouse double-minute 2 homolog (MDM2), an oncogene and repressor of the tumor suppressor p53 (Arrick et al. 1994; Barak et al. 1994; Brown et al. 1999; Hughes and Brady 2005). The MDM2 transcript isoform produced from the distal P1 promoter contains a longer 5′ leader than the one produced from the proximal P2 promoter (Figure 1B) and this P1-derived MDM2 isoform specifically is poorly translated due to the presence of two uORFs in its extended 5′ leader, as established by polysome analyses and reporter assays (Landers et al. 1997; Brown et al. 1999; Jin et al. 2003). These assays had established differential translation of the two individual MDM2 isoforms but had not investigated whether a relationship existed between them.
The integrated mode of gene repression seen for NDC80 in yeast relies on three key features [Figure 1A, (Chen et al. 2017; Chia et al. 2017)]. First, a developmentally regulated switch between alternative promoters for the same gene leads to the usage of different transcription start sites (TSSs). Second, due to upstream open reading frame (uORF)-mediated translational repression, the distal promoter-generated transcript is inefficiently translated. Third, transcription from the distal promoter represses the expression of the canonical mRNA isoform through transcriptional interference associated with co-transcriptional histone modifications. When all three features exist together, and only then, the activation of NDC80 transcription can result in a decrease in translation from this locus. We termed the distal promoter-generated transcript “NDC80LUTI” for long undecoded transcript isoform, because, despite containing the entire NDC80 ORF, NDC80LUTI is not efficiently translated into protein (Chen et al. 2017; Chia et al. 2017). We noted that the regulation at the MDM2 locus shared key features with this LUTI-based mechanism, with the important exception that it was unknown whether there was transcriptional interference between the two MDM2 promoters.
It is well established that MDM2 P2 can be activated by p53 (Wu et al. 1993; Barak et al. 1994; Honda et al. 1997), but little is known about the factors that activate P1 and whether transcription from the P1 promoter affects P2 activity had not been explored. To our knowledge, this was true of all other individually and globally defined examples of alternative transcripts of differential translatability, as transcriptional interference and uORF-based translational control have been topics studied independently, and typically by different labs. Transcriptional interference is an essential feature of the LUTI mechanism, because it causes a toggle between the two transcript isoforms, which is necessary for effective gene expression repression. Transcriptional interference also enables efficient developmental regulation in the case of NDC80. Evidence of transcriptional interference from nearby transcription has previously been established in human cells (reviewed in (Shearwin et al. 2005; Palmer et al. 2011)), but these cases have not involved the production of ORF-encoding mRNAs. Nevertheless, we hypothesized that the type of integrated regulation that is common in yeast might occur at the MDM2 locus. Here, we report evidence that this is indeed the case, based on observed transcriptional interference between the two promoters at this locus. We also observe developmental regulation of the two MDM2 transcript isoforms and conclude that the type of integrated transcriptional and translational regulation that we described as a developmental gene regulatory strategy in yeast is also seen in human cells. These findings suggest value in considering translational and transcriptional regulation not only as independent steps, but rather, as potential collaborators in gene expression outcomes.
Materials and Methods
Cell lines
MCF-7-dCas9 and -dCas9-KRAB cells were cultivated at 37° with 5% CO2 in high glucose Dulbecco’s modified Eagle media (GlutaMax, Gibco) supplemented with 10% FBS and 1% penicillin-streptomycin. K562-dCas9 cell lines were cultivated at 37° with 5% CO2 in RPMI1640 media (Gibco) supplemented with 10% FBS and 10mM HEPES. hESCs (WIBR3 NIH#0079) were maintained in culture as described in (Lengner et al. 2010). The differentiation into definitive endoderm was performed using the STEMdiff Definitive Endoderm Kit (Stem Cell Technologies) following the manufacturer’s instructions. MCF-7-dCas9 and -dCas9-KRAB cells were kindly provided by Howard Y. Chang (Stanford University). K562-dCas9 cells were kindly provided by Jonathan Weissman (University of California, San Francisco). Cell lines were authenticated by STR profiling and were tested to be negative for mycoplasma (MycoAlert Mycoplasma Detection Kit, Lonza).
RNA isolation, cDNA synthesis and quantitative polymerase chain reaction
Total RNA from hESCs differentiating into definitive endoderm and hESCs differentiating into neurons, MCF-7-dCas9, MCF-7-dCas9-KRAB and K562-dCas9 cells was isolated using Trizol (Life Technologies) according to the manufacturer’s instructions. Equal amounts of RNA were primed with random hexamers and reverse transcribed using SuperScript II Reverse Transcriptase (ThermoFisher) according to the manufacturer’s instructions. RNA levels were quantified using SYBR Green/Rox (ThermoFisher) and the StepOnePlus Real-time PCR system (ThermoFisher). Primers used for RT-qPCR are in Table 1.
Table 1. Primers used in this study.
Target gene | Primer | 5′-3′ sequence |
---|---|---|
MDM2PROX | MDM2PROX forward | GTGGCGATTGGAGGGTAGAC |
MDM2PROX reverse | TTGTGCACCAACAGACTTTA | |
MDM2LUTI | MDM2LUTI forward | AAACTGGGGAGTCTTGAGGG |
MDM2LUTI reverse | CAGACATGTTGGTATTGCACAT | |
GAPDH | GAPDH forward | AATCCCATCACCATCTTCCA |
GAPDH reverse | TGGACTCCACGACGTACTCA | |
NANOG | NANOG forward | CCAACATCCTGAACCTCAGCTAC |
NANOG reverse | GCCTTCTGCGTCACACCATT | |
SOX2 | SOX2 forward | CACACTGCCCCTCTCACACAT |
SOX2 reverse | CATTTCCCTCGTTTTTCTTTGAA | |
OCT4 | OCT4 forward | TCGAGAACCGAGTGAGAGGC |
OCT4 reverse | CACACTCGGACCACATCCTTC | |
CXCR4 | CXCR4 forward | AGTGAGGCAGATGACAGATA |
CXCR4 reverse | ACAATACCAGGCAGGATAAG | |
SOX17 | SOX17 forward | GCCGAGTTGAGCAAGATG |
SOX17 reverse | GGCCGGTACTTGTAGTTG | |
MDM2 (ChIP) | MDM2 A forward | GAGTGGAATGATCCCCGAGG |
MDM2 A reverse | GGTTTTCGCGCTTGGAGTC | |
MDM2 B forward | CAGACACGTTCCGAAACTGC | |
MDM2 B reverse | CCAATCGCCACTGAACACAG | |
MDM2 C forward | CACAGATTCCAGCTTCGGAAC | |
MDM2 C reverse | GCCATGCTACAATTGAGGTATACG | |
MDM2 D forward | TGGCCAGTATATTATGACTAAACGA | |
MDM2 D reverse | CACGCCAAACAAATCTCCTA |
Samples for total RNA isolation from hESCs differentiating into neurons (hESC, NPC, neurons D14, neurons D50) were a gift from Helen Bateup [University of California, Berkeley].
CRISPRi knockdowns
sgRNAs targeting MDM2LUTI were designed and cloned into the lentiviral pU6-sgRNA EF1Alpha-puro-T2A-BFP vector. Lentivirus was packaged by co-transfecting sgRNA-expression plasmids and the packaging vectors pCMV-dR8.91 and pMD2.G into 293T cells using the TransIT-LT1 Transfection Reagent (Mirus). Cells were treated with ViralBoost (Alstem) to allow for efficient lentivirus production and lentivirus was harvested 72 h post-transfection. CRISPRi-directed gene knockdown was achieved by transducing MCF-7-dCas9, -dCas9-KRAB and K562-dCas9 cell lines with sgRNA-containing lentivirus in the presence of 8μg/ml polybrene (Millipore Sigma). Successfully transduced cells were puromycin-selected (ThermoFisher; 1.3μg/ml for MCF-7 and 3μg/ml for K562 cells) and harvested 7 days post-infection. The pU6-sgRNA EF1Alpha-puro-T2A-BFP vector was a gift from Jonathan Weissman (Addgene plasmid # 60955).
H3K36me3 Chromatin immunoprecipitation (ChIP)
K562-dCas9 cells (5 × 15cm2 plates per sample) were treated with 1% formaldehyde (16%, methanol free, Ultra Pure, Polysciences) for 10 min at room temperature to crosslink DNA and protein. The crosslinking reaction was stopped by adding 0.125M PBS-glycine and cells were harvested by centrifugation. Cells were subsequently resuspended in ice-cold PBS containing 0.25mM PMSF and 10ug/ml aprotinin (Millipore) and pelleted by centrifugation. Chromatin immunoprecipitation of these pellets was performed as previously described (Testa et al. 2005) with minor modifications. Chromatin was sonicated 50 × 30 sec ON/30 sec OFF with a Bioruptor Pico (Diagenode) to obtain fragment sizes of ∼200 bp. The sheared samples were incubated in RIPA buffer II (10 mM Tris-Cl, pH 8.0, 1 mM EDTA, pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate, 140 mM NaCl) containing protease inhibitors and PMSF, with Dynabeads Protein A (Invitrogen) for 2 h at 4° on rotation. After removal of Dynabeads Protein A, precleared lysates were immunoprecipitated overnight with 4 ug of rabbit anti-mouse IgG (Ab46540, Abcam) or anti-Histone H3 tri methyl lysine 36 (Ab9050, Abcam). Immunoprecipitates were recovered by incubation for 2 h at 4° with previously blocked Protein A Dynabeads in RIPA buffer II (1 μg/μl bovine serum albumin, protease inhibitors, and PMSF). Reverse crosslinked input DNA and immunoprecipitated DNA fragments were amplified with SYBR Green/Rox (ThermoFisher) and quantified with the StepOnePlus Real-time PCR system (ThermoFisher).
Data availability
All the reagents generated in this study are available upon request. Supplemental material available at Figshare: https://doi.org/10.25387/g3.7670699.
Results
A key prediction, if MDM2 were regulated by a LUTI-based mechanism, would be an inverse relationship between the two MDM2 transcript isoforms, such that reduction in transcription from P1 should lead to increased transcription from P2. We were able to reliably assay the levels of the P1- and P2-derived transcripts by reverse transcription followed by quantitative PCR (RT-qPCR) using isoform-specific primers, based on the differential splicing of the two transcripts that results in unique 5′ sequences (Figure S1). To directly test if P1-dependent transcription interferes with P2-dependent transcription, we inhibited transcription from P1 by using CRISPRi (Gilbert et al. 2013; Qi et al. 2013). We first examined MCF-7 breast cancer cells stably encoding the catalytically dead Cas9 (dCas9), which is thought to interfere with PolII elongation when targeted near transcription start sites (Larson et al. 2013; Qi et al. 2013). Expressing each of four different single guide RNAs (sgRNAs) targeting the P1 promoter region led to modest but significant increases, of up to twofold, in the P2-derived MDM2PROX transcript levels, which was associated with the expected reduction of transcription from P1 (Figure 2A and Figure S2A). This result was notable, given that the maximal knockdown of P1 activity was only 40% relative to control cells in these lines (Figure 2A). We tried to enhance the P1 transcriptional knockdown by using CRISPRi in MCF-7 cells that carry a version of dCas9 fused to the Krüppel-associated box (KRAB) transcriptional repression domain (Gilbert et al. 2013). However, targeting of dCas9-KRAB to the P1 promoter led to repression of both the P1 and P2 promoters (Figure S3). This finding is consistent with the long-range effect of the KRAB domain up to 1Kb (Gilbert et al. 2014), beyond the 845 bp distance between the P1 and P2 regulated transcription start sites. Therefore, we performed all subsequent experiments using cell lines that stably expressed dCas9 without the KRAB domain, as this first-generation version of CRISPRi allowed us to achieve promoter-specific repression.
Figure 2.
Downregulation of MDM2LUTI leads to an increase in the expression of MDM2PROX in MCF-7 cells, independent of p53 expression. A. RT-qPCR data displaying the changes of MDM2LUTI and MDM2PROX mRNA expression in MCF-7-dCas9 stable cells. The transcription of MDM2LUTI was inhibited by CRISPRi using four different sgRNAs (#1-4). Data were normalized to GAPDH, and the fold change relative to the expression of MDM2LUTI and MDM2PROX in the cells transfected with an empty vector was calculated. Data points represent the mean of at least 3 independent biological replicates. Error bars represent standard error of the mean (SEM). Two-tailed Student’s t-test was used to calculate the P-values in this figure and all of the subsequent figures. B. RT-qPCR data showing the change in the expression level of TP53, MDM2LUTI and MDM2PROX in MCF-7-dCas9 cells after CRISPRi-mediated TP53 knockdown (left) or CRISPRi-mediated TP53- and MDM2LUTI-double knockdown (right, sgRNA #1 through #4), relative to the cells transfected with an empty vector. Data were normalized to GAPDH. Data points represent the mean of four biological replicates. Error bars represent SEM.
We further probed the relationship between P1 and P2 by knockdown of the gene encoding p53 (TP53) in MCF-7 cells using CRISPRi. Given that p53 is a well-characterized transcriptional activator for P2, it was not surprising that TP53 knockdown resulted in a significant, 43% reduction of the P2-derived MDM2PROX transcript (Figure 2B, left panel). However, additional CRISPRi knockdown of the P1-derived transcript, hereon referred to as MDM2LUTI, still resulted in the transcriptional activation of P2, as evidenced by the 2- to threefold increase in MDM2PROX levels in this background compared to the TP53 knockdown alone (Figure 2B, right panel; Figure S2B; Figure S4). The observation that MDM2LUTI repression leads to an increase in MDM2PROX expression, even in cells with reduced p53 levels, suggests that transcription from P1 actively represses P2 activity and that relief of this repression alone can lead to increased expression of MDM2PROX independent of p53, consistent with transcriptional interference at this locus. To test whether transcriptional interference based on MDM2LUTI occurs in a different cell type, we performed similar experiments in K562, a TP53−/− myeloid leukemia cell line that routinely shows robust CRISPRi-based repression (Gilbert et al. 2014). Inhibition of MDM2LUTI transcription in these cells resulted in a dramatic increase (up to 10-fold) in MDM2PROX expression (Figure 3A and Figure S2C). A range of MDM2LUTI knockdown efficiencies were achieved in this cell line. Consequently, the degree of P1 down-regulation generally correlated with the degree of P2 activation (Figure 3A), suggesting tunability of the transcriptional interference at this locus.
Figure 3.
Downregulation of MDM2LUTI reduces repression-associated histone marks at the P2 promoter. A. RT-qPCR data displaying the changes in MDM2LUTI and MDM2PROX expression levels in a stable K562-dCas9 cell line in which the transcription of MDM2LUTI had been inhibited by CRISPRi using four different sgRNAs (#5, #6, #1, and #7). Data were normalized to GAPDH, and the fold change relative to cells transfected with the empty vector was calculated. Data points represent the mean of at least 3 independent biological replicates. Error bars represent SEM. B. Chromatin immunoprecipitation (ChIP) data displaying H3K36 trimethylation (H3K36me3) enrichment around the proximal TSS (TSS2) in K562-dCas9 cells after CRISPRi-mediated inhibition of MDM2LUTI expression. Location of the four different primer pairs (A, B, C, and D) are shown in the schematic above the graph. Arrowheads indicate the location of uORFs in exon 1 and the yellow box indicates the p53 response element. Data points represent the mean of 4 independent biological replicates. Error bars represent SEM. n.s. = not significant.
H3K36me3 is a co-transcriptionally established modification that occurs in regions downstream of active promoters (Xiao et al. 2003; Bannister et al. 2005; Mikkelsen et al. 2007), and in budding yeast is associated with a decrease in spurious transcription initiation from within transcribed genes (Li et al. 2003; Xiao et al. 2003; Carrozza et al. 2005; Keogh et al. 2005; Kim et al. 2016) and in noncoding RNA transcription-dependent repression of gene promoters (Kim et al. 2012; Van Werven et al. 2012). H3K36me3 is enriched at the proximal NDC80 promoter as a result of NDC80LUTI transcription and is involved in the transcriptional interference seen at the NDC80 locus (Chia et al. 2017). In mammalian cells, H3K36me3 has been implicated in silencing, including the repression of spurious intragenic transcription (Dhayalan et al. 2010; Xie et al. 2011; Wagner and Carpenter 2012; Baubec et al. 2015; Suzuki et al. 2017), but its involvement in promoter repression has been less clear. We found that down-regulation of MDM2LUTI expression resulted in a greater than threefold decrease in the H3K36me3 signal over the P2 promoter (Figure 3B, Figure S5). In contrast, H3K36me3 signal remained high within the MDM2 gene body, likely due to increased MDM2PROX transcription under these conditions. These data are consistent with a mechanism whereby MDM2LUTI expression represses transcription from the P2 promoter through co-transcriptional histone modifications, and provide further support for a model in which the proximal MDM2 promoter is controlled by a similar mechanism to that defined in yeast.
In budding yeast, developmentally controlled switching between the LUTI and canonical mRNA isoforms occurs pervasively during meiotic differentiation (Cheng et al. 2018). To begin to test whether such transcript toggling naturally occurs in human cells, we used two different human Embryonic Stem Cell (hESC) differentiation models. In human hESCs, both MDM2 transcript isoforms were expressed (Figure 4A). When these cells were induced to undergo neuronal differentiation, a transient switch in transcript isoform expression from MDM2PROX to MDM2LUTI was evident between hESCs and neuronal precursors (NPCs) (Figure 4B). We also observed an anti-correlation between MDM2PROXand MDM2LUTI expression as hESCs differentiated into an endodermal fate, as determined by endoderm-specific markers (Figure 4C, Figure S6). This inverse pattern of proximal and distal promoter usage seen during hESC differentiation suggests that the LUTI-based mechanism regulates MDM2 expression during normal cellular differentiation.
Figure 4.
P1- and P2-driven MDM2 transcript isoform toggling can be seen during human embryonic stem cell differentiation. A. RT-qPCR data showing the fold differences of MDM2LUTI and MDM2PROX transcript levels relative to GAPDH expression levels x1000 in human embryonic stem cells (hESCs). Error bars represent the range measured for two biological replicates. B. RT-qPCR data showing the relative expression of MDM2LUTI and MDM2PROX transcripts in human embryonic stem cells (hESCs), neural progenitor cells (NPCs), Day 14 and Day 50 neurons (D14 and D50). Data were normalized relative to MDM2LUTI or MDM2PROX transcript abundance in hESCs. Error bars refer to the range measured for two biological replicates. C. RT-qPCR data showing the changes in the expression of MDM2PROX and MDM2LUTI in hESCs differentiating into endoderm. D1-D4 refers to days after transfer of the hESCs to endoderm differentiation medium. Data were normalized relative to MDM2LUTI or MDM2PROX transcript abundance in hESCs.
Discussion
We report here that an integrated transcriptional and translational regulatory strategy that relies on obligate coupling of transcriptional interference and uORF-based translational repression occurs in human cells. Based on the ubiquitous use of alternative promoters and uORF translation in humans (Ingolia et al. 2011; Floor and Doudna 2016; Wang et al. 2016; Tresenrider and Unal 2018), this type of regulation may control the expression of many mammalian genes. Both the type of transcriptional control described here and the uORF-based translational regulation already established for the distal promoter-derived MDM2 transcript are known modes of gene regulatory control. However, our study shows that transcriptional interference can be combined with the production of alternate transcripts of differential translatability in mammals, in a manner that resembles the LUTI-based regulation seen in yeast. These findings suggest value in revisiting the sequential model of gene expression control that dominates the interpretation of past and current data in favor of a more holistic view of different levels of gene expression control.
Canonical models to explain the prevalence of mammalian alternative promoter usage suggest that one promoter might serve as a “back-up” or that the use of two promoters could simply allow activation by different transcription factors that are present in different cell types (Davuluri et al. 2008). However, in the case of MDM2, we argue that its two promoters are fundamentally different in function. The P1 promoter produces a poorly translated MDM2LUTI transcript and the production of MDM2LUTI from this promoter interferes with P2 activity in cis, reducing the transcription of the well-translated MDM2PROX isoform. Therefore, P1-driven MDM2LUTI mRNA production serves to downregulate MDM2 expression. Further, this repression occurs in a tunable manner (Figure 5). A similar trend was also observed for the Adh gene in fruit fly, which is expressed from two distinct promoters (Jorgensen et al. 2018). Both findings are consistent with the notion that transcriptional interference can be used to tune gene expression, rather than acting as an on-off switch (Chia et al. 2017).
Figure 5.
Model of the LUTI mRNA based mechanism of the MDM2 gene. The MDM2 gene has two promoters, P1 and P2. MDM2PROX is regulated by P2 whereas MDM2LUTI is regulated by P1. In comparison to MDM2PROX, MDM2LUTI is poorly translated because of the existence of two upstream open reading frames (uORFs) in its extended 5′-leader. Top panel: When P1 promoter is active (“ON”), MDM2LUTI transcription establishes H3K36 trimethylation at the downstream P2 promoter and causes repression of P2 (“OFF”). As a result, MDM2LUTI becomes the predominant transcript product from the MDM2 locus. Bottom panel: When P1 promoter is “OFF”, transcriptional repression of the downstream P2 promoter is relieved, culminating in the expression of MDM2PROX. MDM2PROX is efficiently translated, resulting in higher MDM2 translation.
Contrary to traditional gene regulatory models, mRNA and protein abundances generally show poor correlations over developmental programs in genome-scale yeast and vertebrate studies (Peshkin et al. 2015; Cheng et al. 2018). In yeast, hundreds of such cases can be explained by LUTI-based regulation, whereby developmentally regulated transcript distal and proximal promoter usage drives final protein output levels (Cheng et al. 2018). In these conditions, we found that a single developmentally regulated transcription factor could drive distinct sets of canonical and LUTI targets, which resulted in coordinate up- and down-regulation of protein levels for the two target sets (Cheng et al. 2018). We propose that this mechanism may be advantageous for developmental programs, which are typically characterized by multiple transcription-factor driven switches in cell stage, because of the ability to temporally coordinate up- and down-regulation of gene sets at each transition. In principle, whether a gene is in one set or another could be defined simply by the position of the binding site for a given transcription factor relative to the ORF and uORF sequences (Chia et al. 2017; Cheng et al. 2018; Otto and Brar 2018; Tresenrider and Unal 2018). The natural toggling between MDM2 isoforms during differentiation shown here suggests that the broad use of this type of regulation for developmental modulation of gene expression may be conserved.
MDM2 levels are elevated in a variety of cancers (reviewed in (Rayburn et al. 2005)) and this elevation has been attributed in some cases to an increase in translation of the pool of MDM2 transcripts, based on increased transcription from the P2 (Landers et al. 1997; Capoulade et al. 1998; Brown et al. 1999). Much research has focused on identifying alternate transcription factors that can activate P2—as it is clear that transcription can occur from this promoter in the absence of p53—and several have been found (Phelps et al. 2003; Zhang et al. 2012), but relatively little is known about P1 regulation. Our study argues that MDM2 expression levels could be modulated by changes in activation of P1 alone, suggesting a promising new general area for the development of gene regulatory tools that modulate P1 activity, and the activity of other yet-to-be-identified LUTI mRNA promoters, as a means to fine tune gene expression.
Acknowledgments
We are grateful to Howard Chang and Sueng Woo Cho for providing MCF-7-dCas9 and -dCas9-KRAB cell lines; Luke Gilbert, Max Horlbeck, and Jonathan Weissman for providing K562-dCas9 cell lines and for extensive technical help; Helen Bateup, John Blair and Dirk Hockemeyer for providing hESC differentiation samples; Stephen Floor for providing advice and sharing data prior to publication and Christiane Brune for technical support. We thank Barbara Meyer, Jasper Rine, Michael Rape, Folkert van Werven, Jingxun Chen and Eric Sawyer for their valuable feedback on the manuscript; and members of the Tjian and Darzacq labs for tissue culture assistance and advice. This work was supported by funds from the Pew Charitable Trusts (00027344), Damon Runyon Cancer Research Foundation (35-15), National Institutes of Health (DP2 AG055946-01) and Glenn Foundation for Medical Research to E.Ü.; funds from the Pew Charitable Trusts (00029624), the Alfred P. Sloan Foundation (FG-2016-6229), and the National Institutes of Health (DP2 GM-119138) to G.B.; funds from the California Institute of Regenerative Medicine (CIRM, LA1-08013) to X.D., funds from the Howard Hughes Medical Institute (003061) to R.T. and funds from the Shurl and Kay Curci Foundation to L.Y.C.
Author contributions
IH, AT, XD, RT, LYC, EÜ, and GAB designed experimental strategies and methods and performed data analysis; IH, JCB, VJ, AT, CDD, and LYC executed experiments; IH, EÜ, and GAB wrote the manuscript.
Footnotes
Supplemental material available at Figshare: https://doi.org/10.25387/g3.7670699.
Communicating editor: J. Rine
Literature Cited
- Adhya S., Gottesman M., 1982. Promoter occlusion: transcription through a promoter may inhibit its activity. Cell 29: 939–944. 10.1016/0092-8674(82)90456-1 [DOI] [PubMed] [Google Scholar]
- Arrick B. A., Grendell R. L., Griffin L. A., 1994. Enhanced translational efficiency of a novel transforming growth factor beta 3 mRNA in human breast cancer cells. Mol. Cell. Biol. 14: 619–628. 10.1128/MCB.14.1.619 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bannister A. J., Schneider R., Myers F. A., Thorne A. W., Crane-Robinson C., et al. , 2005. Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes. J. Biol. Chem. 280: 17732–17736. 10.1074/jbc.M500796200 [DOI] [PubMed] [Google Scholar]
- Barak Y., Gottlieb E., Juven-Gershon T., Oren M., 1994. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8: 1739–1749. 10.1101/gad.8.15.1739 [DOI] [PubMed] [Google Scholar]
- Barbosa C., Peixeiro I., Romao L., 2013. Gene expression regulation by upstream open reading frames and human disease. PLoS Genet. 9: e1003529 10.1371/journal.pgen.1003529 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Baubec T., Colombo D. F., Wirbelauer C., Schmidt J., Burger L., et al. , 2015. Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature 520: 243–247. 10.1038/nature14176 [DOI] [PubMed] [Google Scholar]
- Boussadia O., Amiot F., Cases S., Triqueneaux G., Jacquemin-Sablon H., et al. , 1997. Transcription of unr (upstream of N-ras) down-modulates N-ras expression in vivo. FEBS Lett. 420: 20–24. 10.1016/S0014-5793(97)01479-8 [DOI] [PubMed] [Google Scholar]
- Brar G. A., Yassour M., Friedman N., Regev A., Ingolia N. T., et al. , 2012. High-resolution view of the yeast meiotic program revealed by ribosome profiling. Science 335: 552–557. 10.1126/science.1215110 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brown C. Y., Mize G. J., Pineda M., George D. L., Morris D. R., 1999. Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene 18: 5631–5637. 10.1038/sj.onc.1202949 [DOI] [PubMed] [Google Scholar]
- Capoulade C., Bressac-de Paillerets B., Lefrere I., Ronsin M., Feunteun J., et al. , 1998. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt’s lymphoma cells. Oncogene 16: 1603–1610. 10.1038/sj.onc.1201702 [DOI] [PubMed] [Google Scholar]
- Carrozza M. J., Li B., Florens L., Suganuma T., Swanson S. K., et al. , 2005. Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription. Cell 123: 581–592. 10.1016/j.cell.2005.10.023 [DOI] [PubMed] [Google Scholar]
- Chen J., Tresenrider A., Chia M., McSwiggen D. T., Spedale G., et al. , 2017. Kinetochore inactivation by expression of a repressive mRNA. eLife 6: e27417 10.7554/eLife.27417 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cheng Z., Otto G. M., Powers E. N., Keskin A., Mertins P., et al. , 2018. Pervasive, Coordinated Protein-Level Changes Driven by Transcript Isoform Switching during Meiosis. Cell 172: 910–923 e916. 10.1016/j.cell.2018.01.035 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chia M., Tresenrider A., Chen J., Spedale G., Jorgensen V., et al. , 2017. Transcription of a 5′ extended mRNA isoform directs dynamic chromatin changes and interference of a downstream promoter. eLife 6: e27420 10.7554/eLife.27420 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Corbin V., Maniatis T., 1989. Role of transcriptional interference in the Drosophila melanogaster Adh promoter switch. Nature 337: 279–282. 10.1038/337279a0 [DOI] [PubMed] [Google Scholar]
- Cullen B. R., Lomedico P. T., Ju G., 1984. Transcriptional interference in avian retroviruses–implications for the promoter insertion model of leukaemogenesis. Nature 307: 241–245. 10.1038/307241a0 [DOI] [PubMed] [Google Scholar]
- Davuluri R. V., Suzuki Y., Sugano S., Plass C., Huang T. H., 2008. The functional consequences of alternative promoter use in mammalian genomes. Trends Genet. 24: 167–177. 10.1016/j.tig.2008.01.008 [DOI] [PubMed] [Google Scholar]
- Dhayalan A., Rajavelu A., Rathert P., Tamas R., Jurkowska R. Z., et al. , 2010. The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. J. Biol. Chem. 285: 26114–26120. 10.1074/jbc.M109.089433 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dieudonné F. X., O’Connor P. B., Gubler-Jaquier P., Yasrebi H., Conne B., et al. , 2015. The effect of heterogeneous Transcription Start Sites (TSS) on the translatome: implications for the mammalian cellular phenotype. BMC Genomics 16: 986 10.1186/s12864-015-2179-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Emerman M., Temin H. M., 1984. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39: 449–467. 10.1016/0092-8674(84)90453-7 [DOI] [PubMed] [Google Scholar]
- Floor S. N., Doudna J. A., 2016. Tunable protein synthesis by transcript isoforms in human cells. eLife 5: e10921 10.7554/eLife.10921 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gilbert L. A., Horlbeck M. A., Adamson B., Villalta J. E., Chen Y., et al. , 2014. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 159: 647–661. 10.1016/j.cell.2014.09.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gilbert L. A., Larson M. H., Morsut L., Liu Z., Brar G. A., et al. , 2013. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154: 442–451. 10.1016/j.cell.2013.06.044 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Greger I. H., Aranda A., Proudfoot N., 2000. Balancing transcriptional interference and initiation on the GAL7 promoter of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 97: 8415–8420. 10.1073/pnas.140217697 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hausler B., Somerville R. L., 1979. Interaction in vivo between strong closely spaced constitutive promoters. J. Mol. Biol. 127: 353–356. 10.1016/0022-2836(79)90335-8 [DOI] [PubMed] [Google Scholar]
- Hinnebusch A. G., Ivanov I. P., Sonenberg N., 2016. Translational control by 5′-untranslated regions of eukaryotic mRNAs. Science 352: 1413–1416. 10.1126/science.aad9868 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hirschman J. E., Durbin K. J., Winston F., 1988. Genetic evidence for promoter competition in Saccharomyces cerevisiae. Mol. Cell. Biol. 8: 4608–4615. 10.1128/MCB.8.11.4608 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Honda R., Tanaka H., Yasuda H., 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25–27. 10.1016/S0014-5793(97)01480-4 [DOI] [PubMed] [Google Scholar]
- Hughes T. A., Brady H. J., 2005. Cross-talk between pRb/E2F and Wnt/beta-catenin pathways: E2F1 induces axin2 leading to repression of Wnt signalling and to increased cell death. Exp. Cell Res. 303: 32–46. 10.1016/j.yexcr.2004.09.014 [DOI] [PubMed] [Google Scholar]
- Ingolia N. T., Ghaemmaghami S., Newman J. R., Weissman J. S., 2009. Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 324: 218–223. 10.1126/science.1168978 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ingolia N. T., Lareau L. F., Weissman J. S., 2011. Ribosome profiling of mouse embryonic stem cells reveals the complexity and dynamics of mammalian proteomes. Cell 147: 789–802. 10.1016/j.cell.2011.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jin X., Turcott E., Englehardt S., Mize G. J., Morris D. R., 2003. The two upstream open reading frames of oncogene mdm2 have different translational regulatory properties. J. Biol. Chem. 278: 25716–25721. 10.1074/jbc.M300316200 [DOI] [PubMed] [Google Scholar]
- Jorgensen V., Chen J., Vander Wende H., Harris D., Wong-Deyrup S. W., et al. , 2018. Tunable Transcriptional Interference at the Endogenous Alcohol Dehydrogenase Gene Locus in Drosophila melanogaster. bioRxiv. 10.1101/452649 [DOI] [PMC free article] [PubMed]
- Keogh M. C., Kurdistani S. K., Morris S. A., Ahn S. H., Podolny V., et al. , 2005. Cotranscriptional set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell 123: 593–605. 10.1016/j.cell.2005.10.025 [DOI] [PubMed] [Google Scholar]
- Kim J. H., Lee B. B., Oh Y. M., Zhu C., Steinmetz L. M., et al. , 2016. Modulation of mRNA and lncRNA expression dynamics by the Set2-Rpd3S pathway. Nat. Commun. 7: 13534 10.1038/ncomms13534 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kim T., Xu Z., Clauder-Munster S., Steinmetz L. M., Buratowski S., 2012. Set3 HDAC mediates effects of overlapping noncoding transcription on gene induction kinetics. Cell 150: 1158–1169. 10.1016/j.cell.2012.08.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Landers J. E., Cassel S. L., George D. L., 1997. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 57: 3562–3568. [PubMed] [Google Scholar]
- Larson M. H., Gilbert L. A., Wang X., Lim W. A., Weissman J. S., et al. , 2013. CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat. Protoc. 8: 2180–2196. 10.1038/nprot.2013.132 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Law G. L., Bickel K. S., MacKay V. L., Morris D. R., 2005. The undertranslated transcriptome reveals widespread translational silencing by alternative 5′ transcript leaders. Genome Biol. 6: R111 10.1186/gb-2005-6-13-r111 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lengner C. J., Gimelbrant A. A., Erwin J. A., Cheng A. W., Guenther M. G., et al. , 2010. Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell 141: 872–883. 10.1016/j.cell.2010.04.010 [DOI] [PubMed] [Google Scholar]
- Li B., Howe L., Anderson S., Yates J. R., 3rd, Workman J. L., 2003. The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II. J. Biol. Chem. 278: 8897–8903. 10.1074/jbc.M212134200 [DOI] [PubMed] [Google Scholar]
- Martens J. A., Laprade L., Winston F., 2004. Intergenic transcription is required to repress the Saccharomyces cerevisiae SER3 gene. Nature 429: 571–574. 10.1038/nature02538 [DOI] [PubMed] [Google Scholar]
- Mikkelsen T. S., Ku M., Jaffe D. B., Issac B., Lieberman E., et al. , 2007. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448: 553–560. 10.1038/nature06008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mueller P. P., Hinnebusch A. G., 1986. Multiple upstream AUG codons mediate translational control of GCN4. Cell 45: 201–207. 10.1016/0092-8674(86)90384-3 [DOI] [PubMed] [Google Scholar]
- Otto G. M., Brar G. A., 2018. Seq-ing answers: uncovering the unexpected in global gene regulation. Curr. Genet. 64: 1183–1188. 10.1007/s00294-018-0839-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Palmer A. C., Egan J. B., Shearwin K. E., 2011. Transcriptional interference by RNA polymerase pausing and dislodgement of transcription factors. Transcription 2: 9–14. 10.4161/trns.2.1.13511 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Peshkin L., Wuhr M., Pearl E., Haas W., Freeman R. M., Jr., et al. , 2015. On the Relationship of Protein and mRNA Dynamics in Vertebrate Embryonic Development. Dev. Cell 35: 383–394. 10.1016/j.devcel.2015.10.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Phelps M., Darley M., Primrose J. N., Blaydes J. P., 2003. p53-independent activation of the hdm2–P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. 63: 2616–2623. [PubMed] [Google Scholar]
- Proudfoot N. J., 1986. Transcriptional interference and termination between duplicated alpha-globin gene constructs suggests a novel mechanism for gene regulation. Nature 322: 562–565. 10.1038/322562a0 [DOI] [PubMed] [Google Scholar]
- Qi L. S., Larson M. H., Gilbert L. A., Doudna J. A., Weissman J. S., et al. , 2013. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152: 1173–1183. 10.1016/j.cell.2013.02.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rayburn E., Zhang R., He J., Wang H., 2005. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets 5: 27–41. 10.2174/1568009053332636 [DOI] [PubMed] [Google Scholar]
- Shearwin K. E., Callen B. P., Egan J. B., 2005. Transcriptional interference–a crash course. Trends Genet. 21: 339–345. 10.1016/j.tig.2005.04.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sterne-Weiler T., Martinez-Nunez R. T., Howard J. M., Cvitovik I., Katzman S., et al. , 2013. Frac-seq reveals isoform-specific recruitment to polyribosomes. Genome Res. 23: 1615–1623. 10.1101/gr.148585.112 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Suzuki S., Murakami Y., Takahata S., 2017. H3K36 methylation state and associated silencing mechanisms. Transcription 8: 26–31. 10.1080/21541264.2016.1246076 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Testa A., Donati G., Yan P., Romani F., Huang T. H., et al. , 2005. Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters. J. Biol. Chem. 280: 13606–13615. 10.1074/jbc.M414039200 [DOI] [PubMed] [Google Scholar]
- Tresenrider A., Unal E., 2018. One-two punch mechanism of gene repression: a fresh perspective on gene regulation. Curr. Genet. 64: 581–588. 10.1007/s00294-017-0793-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Dalfsen, Hodapp K.M, S., Keskin A., Otto G.M., Berdan C.A., et al. , 2018. Global proteome remodeling during ER stress involves Hac1-driven expression of long undecoded transcript isoforms. Dev Cell. 46(2): 219–235.e8. 10.1016/j.devcel.2018.06.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Werven F. J., Neuert G., Hendrick N., Lardenois A., Buratowski S., et al. , 2012. Transcription of two long noncoding RNAs mediates mating-type control of gametogenesis in budding yeast. Cell 150: 1170–1181. 10.1016/j.cell.2012.06.049 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vattem K. M., Wek R. C., 2004. Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc. Natl. Acad. Sci. USA 101: 11269–11274. 10.1073/pnas.0400541101 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wagner E. J., Carpenter P. B., 2012. Understanding the language of Lys36 methylation at histone H3. Nat. Rev. Mol. Cell Biol. 13: 115–126. 10.1038/nrm3274 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang X., Hou J., Quedenau C., Chen W., 2016. Pervasive isoform-specific translational regulation via alternative transcription start sites in mammals. Mol. Syst. Biol. 12: 875 10.15252/msb.20166941 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wethmar K., 2014. The regulatory potential of upstream open reading frames in eukaryotic gene expression. Wiley Interdiscip. Rev. RNA 5: 765–778. 10.1002/wrna.1245 [DOI] [PubMed] [Google Scholar]
- Wethmar K., Smink J. J., Leutz A., 2010. Upstream open reading frames: molecular switches in (patho)physiology. BioEssays 32: 885–893. 10.1002/bies.201000037 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wu X., Bayle J. H., Olson D., Levine A. J., 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126–1132. 10.1101/gad.7.7a.1126 [DOI] [PubMed] [Google Scholar]
- Xiao T., Hall H., Kizer K. O., Shibata Y., Hall M. C., et al. , 2003. Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast. Genes Dev. 17: 654–663. 10.1101/gad.1055503 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xie L., Pelz C., Wang W., Bashar A., Varlamova O., et al. , 2011. KDM5B regulates embryonic stem cell self-renewal and represses cryptic intragenic transcription. EMBO J. 30: 1473–1484. 10.1038/emboj.2011.91 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang X., Zhang Z., Cheng J., Li M., Wang W., et al. , 2012. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J. Biol. Chem. 287: 30468–30476. 10.1074/jbc.M112.373738 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All the reagents generated in this study are available upon request. Supplemental material available at Figshare: https://doi.org/10.25387/g3.7670699.